Meglumine Antimoniate
Formulations: - Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule Indications: - Visceral leishmaniasis - Mucocutaneous leishmaniasis - Cutaneous leishmaniasis Source: EML workbook import

Fresh additions to the Afya Chain catalogue, ready for discovery and procurement.
Formulations: - Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule Indications: - Visceral leishmaniasis - Mucocutaneous leishmaniasis - Cutaneous leishmaniasis Source: EML workbook import
Formulations: - Oral > Solid: 10 mg; 50 mg Indications: - Visceral leishmaniasis - Cutaneous leishmaniasis - Mucocutaneous leishmaniasis Source: EML workbook import
Formulations: - Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate) - Oral > Solid > tablet: 200 mg (as isethionate); 300 mg (as isethionate) - Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection Indications: - Visceral leishmaniasis - Pneumocystosis - Gambiense trypanosomiasis Source: EML workbook import
Formulations: - Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial Indications: - Visceral leishmaniasis - Mucocutaneous leishmaniasis - Cutaneous leishmaniasis Source: EML workbook import
Formulations: - Oral > Solid > dosage form: 100 mg; 50 mg Indications: - Leprosy - Multi-drug resistant Mycobacterium tuberculosis Source: EML workbook import
Formulations: - Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet Indications: - Leprosy Source: EML workbook import
Formulations: - Oral > Liquid: 20 mg per mL Oral > Solid: 150 mg; 300 mg - Oral > Liquid: 20 mg per mL Oral > Solid: 150 mg; 300 mg Parenteral > General injections > IV: 600 mg in vial powder for injection Indications: - Leprosy - Tuberculosis - Other specified tuberculosis Source: EML workbook import
Formulations: - Oral > Solid > dispersible tablet: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package; 75 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 150 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package Indications: - Malaria Source: EML workbook import
Formulations: - Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate) Oral > Solid: 150 mg tablet (as phosphate or sulfate) - Oral > Liquid: 50 mg per 5 mL (base) Oral > Solid > tablet: 150 mg (base) - Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate) Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate) Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate) Oral > Liquid: 50 mg per 5 mL (base) Oral > Solid > tablet: 150 mg (base) - Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate) Indications: - Malaria due to Plasmodium falciparum - Malaria due to Plasmodium ovale - Malaria due to Plasmodium malariae - Malaria due to Plasmodium vivax - Rheumatoid arthritis Source: EML workbook import
Formulations: - Oral > Solid: 250 mg tablet (hydrochloride) - Oral > Solid > tablet: 250 mg (scored) (as hydrochloride) Indications: - Malaria due to Plasmodium falciparum - Malaria due to Plasmodium vivax Source: EML workbook import
Formulations: - Oral > Solid: 500 mg + 25 mg tablet Oral > Solid > dispersible tablet: 250 mg + 12.5 mg tablet - Oral > Solid: 500 mg + 25 mg tablet Indications: - Malaria due to Plasmodium falciparum - Malaria - Malaria due to Plasmodium vivax Source: EML workbook import
Formulations: - Parenteral > General injections > IM: 20 mg per mL in 1 mL ampoule (oily injection); 40 mg per mL in 1 mL ampoule (oily injection) Indications: - Malaria due to Plasmodium falciparum - Malaria due to Plasmodium vivax Source: EML workbook import
Ready to amplify your rewards? Drop your email and we'll be in touch soon.